Sandoz Rituximab Pact Adds To Kyowa Kirin’s Biosimilar Arsenal

Kyowa Hakko Kirin's acquisition of Japanese rights to Sandoz's version of rituximab marks an expansion of the Japanese company's interests in the biosimilars sector, which it sees as 'important' for its business over the coming years.